Asset Management One Co. Ltd. Has $224,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Asset Management One Co. Ltd. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 92.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,490 shares of the medical research company's stock after selling 17,428 shares during the period. Asset Management One Co. Ltd.'s holdings in Charles River Laboratories International were worth $224,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Rothschild Investment LLC lifted its stake in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares during the last quarter. Optiver Holding B.V. bought a new position in Charles River Laboratories International in the 4th quarter worth $37,000. GeoWealth Management LLC lifted its position in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after acquiring an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International during the fourth quarter valued at about $48,000. Finally, Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $0.37 during trading on Friday, reaching $157.12. The company had a trading volume of 247,085 shares, compared to its average volume of 1,027,096. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $254.15. The business's 50 day moving average price is $139.86 and its 200-day moving average price is $152.94. The stock has a market cap of $7.72 billion, a PE ratio of -241.72, a PEG ratio of 5.33 and a beta of 1.49. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same quarter last year, the business posted $2.27 earnings per share. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president owned 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CRL shares. Wall Street Zen cut Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research report on Wednesday, May 14th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Barclays increased their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $171.85.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).